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The effect of superparamagnetic iron oxide
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Mahrooz Malekc and Hamid Reza Madaah Hosseinid
The purpose of this work is evaluating the effect of ultra small superparamagnetic iron oxide nanoparticles
(USPIONs) coatings on encapsulation efficiency in liposomes and cellular cytotoxicity assay. Moreover, we assessed
the effects of surface engineering on the relaxivity of magnetoliposome nanoparticles in order to create a targeted
reagent for the intelligent diagnosis of cancers by MRI. For estimating the effect of nanoparticle coatings on
encapsulation, several kinds of USPIONs coated by dextran, PEG5000 and citrate were used. All kinds of samples
are monodispersed and below 100±10nm and the coatings of USPIONs have no significant effect on
magnetoliposome diameter. The coating of USPIONs could have effect on percentage of encapsulation. The dextran
coated USPIONs have more stability and quality accordingly the encapsulation increased up to 92%, then the
magnetoliposome nano particles have been targeted by Herceptin and anti-HER2 VHH, separately. Over storage
period of four weeks the resulting particles were stable and physico-chemical properties such as size and
zetapotential did not show any significant changes. The relaxivity of contrast agents was measured using a 1.5 T
MRI. The r2/r1 ratio was more than two for all samples which demonstrate the negative contrast enhancing of all
SPION embedded specimens. The high ratio of r2/r1 as well as high r2 is the best combination of a negative contrast
agent as it is obtained for pure magnetite. The value of r2/r1 for all other samples including Herceptin targeted
magnetoliposome, anti-HER2 VHH targeted magnetoliposome and non-targeted magnetoliposome were between
~21 to ~28, which show the magnetite embedded samples have enough negative contrast to be detectable by
MRI. Therefore the HER2 targeted magnetoliposomes are a good and stable candidate as contrast agents in clinical
radiology and biomedical research with minimal cytotoxicity and biocompatibility effects. Copyright © 2016 John
Wiley & Sons, Ltd.
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1. INTRODUCTION
Thanks to its improved resolution and unlimited tissue
penetration, magnetic resonance imaging (MRI) is one of the
most efficient diagnostic modalities in clinical radiology and
biomedical research today (1). MRI ranks among the best
noninvasive methodologies today available in clinical medicine
for assessing anatomy and function of tissues. Its main
advantages are that it allows rapid in vivo acquisition of images
and, under specific conditions, it makes possible imaging at cell
resolution (2,3). In order to improve contrast images, the use of
exogenous substances or contrast agents that alter signal
intensity by selectively shortening the hydrogen relaxation times
of the tissues becomes essential to improve sensitivity and
specificity of MRI. The use of contrast agents such as paramag-
netic Gd3+ (referred to as a positive, T1-contrast agent) or super
paramagnetic iron oxide nanocores (a so-called negative,
T2-contrast agent) is a common practice to enhance detection
limits and visualization of targeted organs or cells (4). The most
commonly used magnetic nanoparticles (MNPs) are composed
of an iron oxide core consisting of crystal magnetite (Fe3O4) or
maghemite (γFe2O3) (5,6). Because of high toxicity of Gd
3+, for
in vitro cell labeling experiments or long-term in vivo cell tracking
studies, the clearance of the particles should be slight. Iron oxide
nanoparticles may potentially provide higher contrast enhance-
ment in MRI than conventional Gd complexes contrast agents
because of their super paramagnetic property. For this reason
ultra small super paramagnetic iron oxide nanoparticles
(USPIONs) are most favorable (7,8).
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USPIONs coating by dextran, citrate or polyethylene glycol
(PEG) and then surface engineering by lipids provides stability
and enhanced biocompatibility to these magnetoliposomes
nanoparticles (MLs) (9). The bedrock of MLs is basically on the
structure and specific features of renowned phospholipid
vesicles. Owing to outstanding properties of liposomes such as
biocompatibility, wide range of surface manipulations,
encapsulation of both hydrophilic (in the inner aqueous cavity)
as well as hydrophobic (in the lipid bilayer) compounds,
therapeutic and diagnostic applications, liposomes are the most
frequently employed carrier vehicles for medical applications
(7,9,10). The underlying principle of most current nanotechnol-
ogy based drug delivery platforms is stood on the enhanced
permeability and retention (EPR) effect has proven to be a key
pharmacokinetic feature for existing nanomedicines but this
mechanism is not applicable to potential nanomedicines that
target circulating tumor cells in circulation (11). Active targeting
of a nanoparticle is a way to minimize uptake in normal tissue
and increase accumulation in a tumor. Strategies for active
targeting of tumors usually involve targeting surface membrane
proteins that are up regulated in cancer cells (12–15).
One great challenge with active targeted delivery of magnetic
nanocarriers is variation in magnetic nanoparticles properties
after chemical surface modification. The coating molecules
increase water solubility and decrease toxicity and immunoge-
nicity (16). However, the coating may interact with the surface
atoms of the magnetic core to form a nonmagnetic layer,
reducing its effective size and the total amount of magnetic
phase, whereas the effective size and especially the concentra-
tion of the magnetic phase are important factors in many bio-
medical applications (17,18).
The majority of researches concerning the effect of nanoparti-
cle coating on cellular uptake, circulatory blood half-life, and the
ability to accumulate in tumors is derived from investigations
with nonmagnetic nanoparticles, whereas information
concerning the effect of MNP coatings and targeting on
relaxometry are still rare. In some studies the decrease was
attributed to the surface chemical interaction between the
stabilizing surfactant and the magnetic core. Recently, Vestal
and Zhang showed that the coercivity and saturation magnetiza-
tion of manganese ferrite nanoparticle change after surface
modification with para-substituted benzoic acid ligands and
substituted benzene ligands (17,19). Only a few studies have
been reported on the reduction of the magnetic phase in coated
nanoparticle systems (20), and none have focused on the
changes made by the surface engineering and antibody
targeting. Actually different kinds of targeting agents such as
monoclonal antibodies (mAbs) (13) and peptides may have
detrimental effects on biocompatibility and relaxometry. In this
study we decide to utilize Herceptin (a mAb against HER2) and
anti-HER2 VHH (a small molecule as a small ligand). Herceptin
interferes with the HER2/neu receptor (the second member of
the EGFR (ErbB) family) and since gene amplification and/or
over-expression of HER2 occur in 20–30% of breast cancers, it
makes it an attractive target for intelligent theranostics.
Furthermore VHHs are the next generation of therapeutic agents
that ideally encompass the advantages of small molecules as
well as the benefits of mAbs. VHHs are smallest available intact
antigen-binding units in comparison with mAbs, derived from
functional heavy-chain antibodies (HCAbs) devoid of light chains
(21). In current work, we address the effects of different kinds of
magnetite coatings (dextran, PEG5000 and citrate coated
USPIONs) on encapsulation efficiency and cytotoxicity then the
effect of targeting will be investigated by anti-HER2 VHH and
whole Herceptin antibody on the relaxivity of
magnetoliposomes.
2. MATERIALS AND METHODS
2.1. Chemicals and reagents
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), cholesterol,
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(poly-
ethylene glycol)-2000] (ammonium salt) (DSPE-mPEG(2000)) and
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide
(polyethylene glycol)-2000] (ammonium salt) (DSPE-PEG(2000)
maleimide) were purchased from Avanti polar lipids. USPIONs coated
by dextran and PEG5000 provided in (Biomaterial laboratory, Sharif
University of Technology, Tehran, Iran) (22) and USPIONs coated by
citrate were bought from Institute of Teb Sanat Rahyab (Tehran, Iran).
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT)
salt was bought from Sigma-Aldrich (St. Louis, MO, USA). The Quick
Start™ Bradford protein assay kit provided from Bio-Rad Laboratories
Inc. PrestoBlue™ Cell Viability reagent was obtained from Life
technology (Carlsbad, CA, USA). Plastic disposable 96-well tissue
culture dishes, pipettes and tubes were purchased from Nunc
(Roskilde, Denmark).
2.2. Cell culture conditions
BT-474 (HER2-overexpressing breast cancer cell line) and
MDA-MB-231 (HER2 and estrogen receptor negative breast
cancer cell line) were grown in RMPI (100 U/mL penicillin,
100μg/mL streptomycin and 2mM/L glutamine) with or without
10% FBS and SK-BR-3, MCF-10A (human normal breast epithelial
cell line) was cultured in the DMEM/F12 medium supplemented
with 5% horse serum, 100mg/mL EGF, 1mg/mL hydrocortisone,
10mg/mL insulin, 100 units/mL of penicillin and 100μg/mL of
streptomycin.
2.3. Preparation of magnetoliposomes
The magnetoliposomes were prepared using the classical film
rehydration method followed by extrusion according with the
work of Sabate et al. (2008) with some modifications (23). In brief,
the lipids DPPC: cholesterol: DSPE-PEG2000: malemide-PEG2000-
DSPE in a molar ratio of 7:2.5:0.4:0.1 and in amounts required to
obtain a final lipid concentration of 50mg/mL, were dissolved in
a mixture of chloroform and methanol (9:1, volume ratio) in a
round-bottom flask and dried in a rotary evaporator under
reduced pressure at 45 °C to form a thin film on the flask. After
the complete removal of the chloroform, the lipid film was
hydrated with the appropriate amount of the mixture of water
and USPIONs to give a lipid concentration of 50mg/mL for 1 h.
Multilamellar liposomes (MLV) were downsized to form
oligolamellar vesicles by mini-extruder (Avanti Polar Lipids, AL,
USA) with polycarbonate membranes (Avanti Polar Lipids) with
pore diameters of 100 nm 21 times at 45 °C.
2.4. Particle characterization
2.4.1. Size and electro kinetic determination
In ferrofluid and magnetoliposomes, the mean and distribution
of the particle size were determined by dynamic light scattering
at 25 °C with a Zetasizer Nano ZS90 (Malvern, UK). To measure
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particle size distribution of the dispersion, a polydispersity index
(PDI), ranging from 0.0 for an entirely monodisperse sample to
1.0 for a polydisperse sample, was used. Electrophoretic mobility
was measured with a Zetasizer Nano ZS90 (Malvern, UK) too.
Magnetoliposomes were diluted with PBS 10mM until a
concentration of approximately 0.2 g/L of magnetite. To avoid
that magnetoliposomes can settle due to the high density of
the magnetite, the measurement was carried out with three
different samples.
2.4.2. Transmission electron microscopy
The final magnetoliposomes were detected by transmission
electron microscopy (TEM) using a Hitachi H-7500 transmission
electron microscope. Sample was arranged by placing a drop
of magnetoliposomes onto a 400-mesh copper grid coated with
carbon film, and it was tolerated to dry in the air before
introduction into the microscope. Scanned images were then
analyzed in Adobe® ImageReady™, version 3.0, to determine
approximate diameters.
2.5. Purification of magnetoliposomes
After the process of sample sizing, non-entrapped ferrofluid parti-
cles were removed by size exclusion chromatography (SEC) with
a 1×30 cm chromatography column (sepharose CL4B, Sigma-
Aldrich, St. Louis, MO, USA) saturated with lipids before sample elu-
tion. The elution profiles of liposomes and IONPs were previously
identified to validate the separation procedure in order to obtain
the desired iron oxide/lipid ratio for a constant lipid concentration.
2.6. Assay of magnetite
At first, cell pellets are mineralized in a volume of 5N HCl
(100–400μL depending on the cell number) for 4 h in a water
bath at 80 °C or during 24–72 h in a water bath at 37 °C. The
standard curve was accomplished by 100μL of aqueous
solutions containing 0.22–2.2μg Fe of the USPION suspension
(~39–390μM Fe), or 0.625–2.5μg Fe of ferric iron solution
(~112–448μM Fe) were treated over 24 h at 37 °C with 100μL
5N HCl, it follows that the solution was mixed with 100μL of
5% Potassium Ferrocyanide, Perl’s reagent, in distilled water.
The absorbance of the solution was read at 630 nm or 650 nm
after 15min.
2.7. Assay of phospholipids
Phospholipid content in magnetoliposomes was determined by
the method of Steward-Marshall (1980) and phosphate assay
kit (Colorimetric) (Abcam, Cambridge, USA). It was confirmed in
advance that the presence of ferritine had no influence on color
development. An aliquot of 50μL of magnetoliposomes was
mixed with 500μL of CHCl3, before adding 500μL of the reagent
(0.1M ammonium ferrothiocyanate). After shaking energetically
for 45 s, the sample was centrifuged for 10min at 2000 rpm.
The absorbance of the aqueous phase was read at 490 nm. The
calibration curve was performed with several amounts of a
40mM solution of phosphatydylcholine in CHCl3.
2.8. Encapsulation efficiency determination
For establishment the best magnetite/phospholipid ratio,
liposomes containing 5–45mg of magnetite per mol of phos-
pholipids were prepared. After SEC purification, the amount of
magnetite and the phospholipid content were determined, the
magnetite/phospholipid ratio was calculated, and this value
was compared to the initial pre-SEC values to obtain the
percentage of encapsulation. In order to evaluate the effect of
nanoparticle coatings on encapsulation, several kinds of
USPIONs coated by dextran, PEG5000 and citrate were used.
2.9. Cell viability and metabolic activity
2.9.1. MTT assay
To evaluate the effect of nanoparticles on the viability of the
cells, a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was established. For this purpose BT-474,
SK-BR-3, MCF10-A and MDA-MB-231 cell lines were seeded on
96-well microtiter plate at a density of 4 × 104, 3 × 104, 2 × 104
and 3 × 104 respectively, then incubated with magnetoliposomes
(200 and 400μg Fe/ml), liposomes (adjust to magnetoliposomes)
and magnetites coated by dextran, PEG5000 and citrate (200 and
400μg Fe/ml) for 24 and 48 h. After incubation, all samples were
washed three times with PBS (without Mg2+ and Ca2+) and
further incubated for 4 hours at 37 °C and 5% CO2 with MTT
solution (0.5 g/L in medium) and phenol red free medium
according to data sheet until purple precipitate is visible. The
medium was then removed and 100μL lysis buffers (1% Triton
X-100 in isopropanol) were added to each well and extensively
mixed. The optical density was then measured at 570 nm using
a Nunc absorbance plate reader (Roskilde, Denmark). The
viability of cells was represented as percent of viability
normalized to non-labeled samples (100%).
2.9.2. CytoTox 96® cell membrane permeability assay
In order to overcome any of the nano particle-associated
problems, it is important to add control samples and preferably
to use different assays which are based on different cellular
parameters. The CytoTox 96® assay quantitatively measures
lactate dehydrogenase (LDH), a stable cytosolic enzyme that is
released upon cell lysis. Released LDH in culture supernatants
is measured with a 30min coupled enzymatic assay, which
Table 1. Characteristics of the obtained PEGylated magnetoliposomes with several concentrations of Citrate coated USPIONs.
ML1, ML2 … ML7 are magnetoliposome samples with several amounts of magnetite/mol of phospholipid (5–45 g Fe3O4/mol PL)
Citrate coated USPIONs ML1 ML2 ML3 ML4 ML5 ML6 ML7
gFe3O4/mol PL 5 10 15 20 25 35 45
gFe/mol PL 3.6 7.1 10.7 14.3 17.8 25.0 32.1
% encapsulation 7 ± 0.5 8.5 ± 0.1 9 ± 0.1 9.5 ± 0.1 10 ± 0.8 9 ± 0.1 8 ± 0.2
Z-average hydrodynamic diameter (nm) 105 109 110.5 109.5 112 111 112
polydispersity index (PDI) 0.1 0.1 0.1 0.1 0.1 0.1 0.1
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results in the conversion of a tetrazolium salt (INT) into a red
formazan product. The amount of color formed is proportional
to the number lysed cells. Because various cell types contain
different amounts of LDH, we prepared a preliminary experiment
using our target cell populations to determine the optimum
number of target cells to use with the CytoTox 96® assay and
to ensure an adequate signal-to-noise ratio. The LDH positive
control supplied may be used to verify that the LDH assay is
functioning properly. After 4 h treatment of the cells with the
samples as mentioned above according to manufacture
protocol, the viability of cells was represented as percent of
viability normalized to non-labeled samples (100%) as
mentioned above.
2.9.3. PrestoBlue™ cell viability assay
PrestoBlue™ cell viability reagent is a ready-to-use reagent for
rapidly evaluating the viability and proliferation of a wide range
of cell types. Presto blue assay was done according to the
manufacturer’s protocol. After 24 h treatment of the cells with
the samples as mentioned above, the cells were washed and
incubated with PB reagent. The changes in cell viability were
detected using both, fluorescence and absorbance spectroscopy.
The absorbance was recorded at 570 nm after 2 h incubation of
mentioned cells with PB reagent, whereas the fluorescence was
read (excitation 570 nm; emission 610 nm) at recommended
time of incubation (20min and 2 h endpoint). The cell viability
was expressed as a percentage relative to the non-treated cells.
2.10. Preparation of anti-HER2 targeted
magnetoliposomes
Targeting was done by both Herceptin and anti-HER2 VHH for
comparison. In order to conjugate thiolated VHH to liposomes,
the buffer was exchanged with phosphate buffer by amicon filter
30000KDa and the pH was adjusted to 7.0. To optimize
immunoliposomes preparation, the samples were incubated for
1, 2, 3, and 24 h at 20 °C and 4 °C under constant and gentle
shaking. In all samples, 50mg liposome was added to 1.8 g/L
VHH and the volume of the samples was adjusted to 1mL with
phosphate buffer (pH 7). With the purpose of Herceptin
conjugation, the antibody thiolated with 50-fold molar excess
of 2-iminothiolane for 2 h and the buffer was exchanged as
described above, an aliquot (1 g/L) of thiolated Herceptin
solution in phosphate buffer pH 7 were added to 50mg
liposome under constant gentle shaking at room temperature
for 1 h and the volume of the samples was adjusted to 1mL with
phosphate buffer (pH 7). Conjugation was confirmed by
SDS-PAGE followed by silver staining (24).
2.11. Storage stability of anti-HER2 VHH targeted
magnetoliposomes
Nanoparticles conjugated with ati-HER2 VHH were prepared and
analyzed as described above. Without any additional agents the
particle samples were stored in phosphate buffer pH 7 at 4 °C for
a period of 4weeks. Once a week an aliquot (100μL) of the
nanoparticle suspension was analyzed for unbound anti-HER2
VHH using SEC as described above. Additionally, particle size
and zetapotential were measured.
2.12. Phantom analysis
The MRI contrast efficiency of the samples was assessed at room
temperature by investigating the hydrogen relaxivity (the
relaxation rates per iron concentration, expressed in mM). In vitro
study was performed by 1.5 T GE MR Scanner at 25 °C with a
90mm×90mm field of view (FOV), one acquisition, matrix size
of 256 × 196 pixels and 5mm slice thickness. All sample series
were placed in 1.5mL tubes in a water-filled plastic container
to avoid any susceptibility artifact due to air. T1 and T2-weighted
images with different sample concentrations (0.1, 0.2, 0.4, 0.6, 1
and 1.2mM Fe/mL) were analyzed quantitatively. The r1 and r2
parameters were calculated by calculating the slope of (1/T1)
and (1/T2) plots versus concentrations. T1 weighted Spin-echo
images with fixed TE = 12ms and multiple TR = 240, 500, 1000,
2000 and 4000ms were applied to calculate R1 in different
concentrations. T2 weighted Spin-echo images with fixed
Table 2. Characteristics of the obtained PEGylated magnetoliposomes with several concentrations of PEG coated USPIONs. ML1,
ML2 … ML7 are samples with several amounts of magnetite/mol of phospholipid (5-45 g Fe3O4/mol PL)
PEG coated USPIONs ML1 ML2 ML3 ML4 ML5 ML6 ML7
gFe3O4/mol PL 5 10 15 20 25 35 45
gFe/mol PL 3.6 7.1 10.7 14.3 17.8 25.0 32.1
% encapsulation 32± 0.8 49 ± 0.5 23 ± 0.7 22 ± 0.6 20 ± 0.5 21 ± 0.4 20 ± 0.7
Z-average hydrodynamic diameter (nm) 90 95 98 99 100 102 105
polydispersity index (PDI) 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Table 3. Characteristics of the obtained PEGylated magnetoliposomes with several concentrations of Dextran coated USPIONs.
ML1, ML2 … ML7 are samples with several amounts of magnetite/mol of phospholipid (5-45 g Fe3O4/mol PL)
Dextran coated USPIONs ML1 ML2 ML3 ML4 ML5 ML6 ML7
gFe3O4/mol PL 5 10 15 20 25 35 45
gFe/mol PL 3.6 7.1 10.7 14.3 17.8 25.0 32.1
% encapsulation 12± 0.1 24 ± 0.7 14 ± 0.2 47 ± 0.1 44 ± 0.5 41 ± 0.6 91 ± 0.9
Z-average hydrodynamic diameter (nm) 100 119 112.5 106.5 112.9 89.0 98.0
polydispersity index (PDI) 0.1 0.1 0.1 0.1 0.1 0.1 0.1
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TR= 4000ms and multiple TE =12, 24, 36 and 48ms were applied
to calculate R2 in different concentrations.
2.13. Statistical analysis
The different experimental groups within the study were
compared by using the one way-ANOVA and MANOVA test.
The comparisons between the pairs of groups were performed
with the Manhane test. A probability of less than 0.05 (P< 0.05)
was used for statistical significance.
3. RESULTS AND DISCUSSION
3.1. Characterizations of magnetoliposomes
In order to confirm the physical characterization of
magnetoliposomes, several usual techniques were used. As-
prepared magnetoliposomes (containing 5–45 g of
magnetite/mol of phospholipid (Pl)) were brownish appearance
and highly soluble in water.
3.1.1. Size and electro kinetic determination
After preparation of magnetoliposomes, the average diameter and
distribution of nanoparticles were determined by Zetasizer Nano
ZS90 at 25 °C and expressed as z-average. After optimization of
encapsulation by serial concentrations of USPIONs, the results
show the expected general trend of an increase in the particle di-
ameter with an increase in USPIONs concentration but statistically
there’s no significant difference among magnetoliposomes with
different amounts of Fe3O4 in size and z-average (Tables 1–3). All
the samples are monodispersed and below 100± 10nm corre-
sponding to the diameter of polycarbonate filter. After surface
modification with VHH (Fig. 1) an average size of 110±10nm with
PDI below 0.1 and a surface charge of -5mV were obtained. With-
out VHH modification the average size was 100±10nm and the
zetapotential of 0.42mV near to neutral. However, negative
zetapotential after conjugation shows the VHH induces a
negative charge on the surface of targeted magnetoliposomes,
in order to minimize nonspecific interaction with blood
components and off-target cells. The coatings of USPIONs have
no significant effect on magnetoliposome diameter and the sizes
of the samples are accordance with the poly carbonate filter
diameter.
3.1.2. TEM
Figure 2 was obtained by TEM without staining the samples.
From these micrographs, we can see that the magnetoliposomes
prepared by the improved method of rotary film evaporation
and high-pressure extrusion were spherical, with different size,
nearly <60 nm predominantly, and most of them were single
room. USPION particles were found in a higher extent inside of
the liposomes although their distributions were rather irregular.
Entrapped USPION particles did not present any specific
interaction with the lipid bilayer and they retained good
dispersibility.
Figure 1. Confirmation of antibody conjugation on the surface of lipo-
somes by coomassie blue staining. The heavier band than VHH to the 3
KD, represent the conjugation of VHH to the surface of
magnetoliposomes. 1) protein ladder, 2) purified free VHH and 3) conju-
gated VHH to ML.
Figure 2. TEM image of MLs without staining, showing the phospho-
lipid bilayer surrounded the electron dense iron oxide cores.
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3.2. Purification and encapsulation efficiency
determination
After size exclusion chromatography (SEC) purification by
sepharose CL4B, liposomes were recovered completely free of
contaminating external ferrofluid in elutes corresponding to
the void volume of the column. The encapsulation efficiency
was determined with varying initial weight ratios of magnetite
to phospholipids, as we wanted to determine the effects of
magnetite coatings on encapsulation efficiency, different kinds
of coatings; dextran, PEG5000 and citrate were determined
(Tables 1–3). In all steps, the initial amounts of phospholipids
were identical and the synthesis process was the same.
Magnetite and phospholipid concentrations were determined
before extrusion and after purification by SEC. According to
Table 1, the amount of encapsulated iron steadily increases as
the starting iron/phospholipid ratio increases from 5 to 45 g
Fe3O4 /mol Pl. The low percentage of encapsulation at higher
concentration ratios can be explained by the loss of magnetite
during the extrusion process, since the polycarbonate
membrane is completely covered by a dark film of magnetite.
Although magnetite is much smaller than the
magnetoliposomes, the formation of clusters of ferrofluid
particles could explain the presence of magnetite on the surface
of membranes (25). The percentage of dextran coated USPIONs
encapsulation, which has rapid increase at the lowest initial
concentrations (from 5g Fe3O4 /mol Pl to 25 g Fe3O4 /mol Pl),
remained almost constant (from 25 g Fe3O4 /mol Pl to 45 g
Fe3O4 /mol Pl) and finally decreased (in concentrations greater
than 45 g Fe3O4 /mol Pl). We obtained the best percent of
encapsulation about 92% in 45 g Fe3O4 /mol Pl for dextran
coated USPIONs, about 50% in 10 g Fe3O4 /mol Pl for PEG coated
USPIONs and 10% in 25 g Fe3O4 /mol Pl for citrate coated
USPIONs. Of course the quality and stability of USPIONs coatings
has a considerable impact on the encapsulation efficiency. In this
experiment the dextran coated USPIONs have more stability and
quality accordingly the encapsulation increased. We choose
dextran coated USPIONs by 45 g Fe3O4 /mol Pl concentration
ratios for the best of experimental tests. Consequently, the kind
of USPIONs coating could have effect on percentage of
encapsulation. This may be due to inappropriate interactions
between USPIONs coatings and PEGylated magnetoliposomes.
Figure 3. Cell viability assay (MTT) for HER2 positive (SK-BR-3 and BT-474) , HER2 negative (MDA-MB-231) and normal breast cell line (MCF10-A) incu-
bated with magnetoliposome (ML1: 200 μg Fe/mL , ML2: 400 μg Fe/mL), liposome (L1: liposome 5mgPC/ml, L2: liposome 10mgPC/ml), Dextran coated
USPION (D1: 200 μg Fe/mL, D2: 400 μg Fe/mL), PEG coated USPION (P1: 200 μg Fe/mL, P2: 400 μg Fe/mL) and citrate coated USPION (C1: 200 μg Fe/
mL, C2: 400 μg Fe/mL) , after 24 h (A) and 48 h (B) of incubation. The error bars indicated are mean SEM (n ¼ 10). For the cell viability, relative values
are given to those of control samples not incubated with any particles but otherwise treated identically.
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3.3. Comparison of the cytotoxicity effects of USPIONs
coatings, ML and vesicles
To compare the cellular toxicities of dextran, PEG5000 and citrate
coated USPIONs, MLs and vesicles, we evaluated cell viability in
BT-474, SK-BR-3 as HER2 positive breast cancer cell lines,
MDA-MB-231 as HER2 negative breast cancer cell lines and
MCF10-A as breast normal cell line. These cell lines were
incubated with dextran, PEG5000 and citrate coated USPIONs,
MLs and iron oxide-free vesicles, all containing the same
phospholipid ingredients and identical preparation process. All
types of particles were given at two different iron concentra-
tions, being 200 and 400 g Fe/L (26–28). These concentrations
correspond to the lipid concentration for iron oxide-free vesicles.
The viability assay (MTT) after 24 and 48 h (Fig. 3 A, B), LDH assay
Figure 4. A) CytoTox 96® cell membrane permeability assay. B) PrestoBlue™ cell viability assay. HER2 positive (SK-BR-3 and BT-474) , HER2 negative
(MDA-MB-231) and normal breast cell line (MCF10-A) incubated with magnetoliposome (ML1: 200 μg Fe/mL, ML2: 400 μg Fe/mL), liposome (L1: lipo-
some 5mgPC/mL, L2: liposome 10mgPC/mL), Dextran coated USPION (D1: 200 μg Fe/mL, D2: 400 μg Fe/mL), PEG coated USPION (P1: 200 μg Fe/mL,
P2: 400 μg Fe/mL) and citrate coated USPION (C1: 200 μg Fe/mL, C2: 400 μg Fe/mL), after 4 h and 24 h of incubation for CytoTox 96® cell membrane
permeability and PrestoBlue™ cell viability assay respectively. Values for every sample are relative to that of control cells not incubated with MLs or
inhibitors.
Figure 5. Storage stability of anti-HER2 targeted magnetoliposomes.
Particle diameter and zetapotential were recorded over a time period
of 4 weeks (n = 3; mean ± SD).
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after 4 h (Fig. 4A) and PrestoBlue® viability assay (Fig. 4B) after
24 h for all types of nanoparticles are assessed separately for
further confirmation. As anticipated, there is no significant
cytotoxicity among samples during incubation times. Looking
upon cell permeability or LDH assay, it was observed that all
types of samples have no significant effects on cell membrane
stability and permeability. The results indicating that in the
actual conditions the iron oxide cores themselves did not play
a crucial role but that the effects were solely due to the lipid
bilayer. Therefore the inert magnetoliposomes are good
candidate as contrast agents in clinical radiology and biomedical
research today with minimal cytotoxicity and incompatibility
effects.
3.4. Preparation of VHH-modified nanoparticles
Magnetoliposomes were obtained using the classical film
method in a rotary evaporator under reduced pressure. The
surface of the particles is PEGylated and activated by
PEG2000-DSPE and malemide-PEG2000-DSPE respectively. The
PEG chains introduced on the particle surface are responsible
for the so-called ‘stealth effect’, preventing non-specific cell
binding as well as adsorption of plasma proteins, in addition,
provides a reactive malemide group which can be used for
covalent binding of thiolated VHH by thioether bond
formation (29,30). The SEC analysis of the supernatants
revealed, that the VHH was quantitatively bound to the
nanoparticle surface by effective percent near to 70% (Fig. 1).
Therefore, the amounts of introduced sulfhydryl groups were
optimized to achieve the highest efficiency in VHH
conjugation to the particle surface. Since almost one free
sulfhydryl group (per VHH molecule) was introduced, the
number of adsorptive VHH binding to the particle surface
could be roughly anticipated. Within our study it was
observed, that increasing the conjugation time and tempera-
ture caused a slight problems in cell attachment and uptake.
Likewise, the magnetoliposome’s stability was decreased and
some precipitation was appeared. Moreover, after a reaction
time of 24 h multimeric conjugates have occurred. Thus, an
average 27 μg VHH were attached per mg nanoparticle which
corresponds to 58 VHH molecules per nanoparticles.
Figure 6. MR images of SPION samples in vials, A) T1 (TR = 500ms) and (TE = 11ms). B) T2 (TR = 4000ms) and (TE = 12ms). C) T2
* (TR = 300ms) and
(TE = 12ms) for different concentrations of samples. S1: magnetite. S2: Herceptin targeted magnetoliposome. S3: Nanobody targeted
magnetoliposome. S4: non targeted magnetoliposome. In vitro study was performed by 1.5 T GE MR Scanner at 25 °C with a 90mm× 90mm field of
view (FOV), one acquisition, matrix size of 256 × 196 pixels and 5mm slice thickness.
Figure 7. A) Longitudinal, R1 relaxation rates versus concentration for
sample 1 to sample 4 respectively. B) Transverse, R2 relaxation rates ver-
sus concentration for sample 1 to 4 respectively.
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3.5. Storage stability of anti-HER2 VHH targeted
magnetoliposomes
Storage stability of anti-HER2 VHH modified nanoparticles for the
stability investigations, released anti-HER2 VHH was determined
over a storage period of 4weeks. Over the total storage time
no anti-HER2 VHH was detectable in the supernatant. Likewise,
the physicochemical properties _size and zetapotential_ did
not change significantly (Fig. 5). Thus, targeted
magnetoliposomes have long-term stability in biological
solutions, such as buffer or aqueous phases, for at least one
month. In some cases non covalent nanoparticles targeting show
problems with colloidal storage stability. Therefore, in order to
simplify the nanoparticle system we established a direct covalent
linkage of anti-HER2 VHH. In a first step anti-HER2 VHH was
thiolated and afterwards the thiolated VHH was coupled on the
surface of the nanoparticles. Storage stability of the system over
4weeks was demonstrated. This stability is required for using the
system in cell culture and in vivo assays.
3.6. Magnetic properties of targeted and non-targeted MLs
According to T1, T2 and T2* weighted images with multiple TR and
TE (Fig. 6), different signal intensities could be seen in a
concentration dependent manner. So, different T1 and T2
relaxation times have been achieved as a result of different
concentrations. The R1 and R2 map images were measured as
shown in Fig. 7 (A), (B), and Table 4. The r2/r1 ratio was more than
2 for all USPION embedded specimens. The high r2/r1 as well as
high r2 is the best combination of a negative contrast agent or T2
contrast agent, as it is obtained for pure magnetite (sample 1).
These facts mean that the lipid composition of liposomes
influences the relaxivity produced by the contrast agents
encapsulated or incorporated within them. The engineering of
nanoparticles with high relaxivity (and therefore contrast) is thus
highly advantageous for specific targeting of receptors or
antigens. Furthermore, the conjugation of biomolecules such as an-
tibodies (average diameter ~10nm) to the surface of nanoparticles
for specific targeting may have an effect on the R2 characteristics
due to the increase of overall apparent thickness of the coating. De-
pending on the effect of these biomolecules on surrounding water
and its diffusion around the particle, such attachments may result in
a decrease in the r2 relaxivity of the contrast agent. The amount of
r2/r1 for all other samples including HER2 targeted
magnetoliposome (sample 2), VHH targeted magnetoliposome
(sample 3) and non-targetedmagnetoliposome (sample 4) were be-
tween ~21 to ~28, which show the Magnetite embedded samples
have enough negative contrast to be detectable by MR Imaging.
Sample 3 shows the highest r2/r1 value, although it suffer the
lowest r1 value. The near r2/r1 values for samples 4 and 2 show that
the anti HER2 loading process was not affected the amount of mag-
netite content of non-targeted magnetoliposome. As indicated, the
encapsulation of a hydrophilic Fe-based contrast agent in lipo-
somes results in reduction of the relaxivity. Because of their ability
to provide tumor targeted imaging, anti-HER2 MLs represent a po-
tentially powerful strategy for the diagnostics and treatments of
HER2-overexpressing cancers. These nanocarriers bind to and inter-
nalize in target cells but are non-reactive with normal cells.
4. CONCLUSION
In the present work, we have developed a set of physico-
chemical protocols to prepare magnetic nanoparticles that
possess accurate sizes, shapes, compositions, relaxivities, stability
and surface charges. These features, in turn, can be harnessed to
adjust the toxicity and stability of the nanoparticles and, further,
to load functionalities, via various mechanisms, onto the
nanoparticle surfaces. These capabilities have greatly expanded
the role of magnetic nanoparticles, enabling real-time targeting,
imaging, and therapy. Classical MLs targeted by anti-Her2 VHH
and Herceptin, were used as a model system for analysis the
effect of surface decorating on relaxometry. It was shown that
inert and PEGylated MLs and also free USPIONs are biocompati-
ble with minimum severe effects on cell plasma membrane.
Previous studies also confirmed that MLs toxicity depends on
the nature of the lipid, the size and physico-chemical
characteristics of the liposome formulations (28). The need to
assess the effect of targeting on the properties of nano particles
caused we analyzed anti-Her2 VHH and Herceptin conjugated
MLs as contrast agents in MRI. The high ratio r2/r1 as well as high
r2 in targeted MLs are the best combination of a negative
contrast agent as it is obtained for pure magnetite. While the
outlook is clear and exciting, it is fair to admit that we are at a
relatively early stage of development. In fact, there is a complex
interplay between coating thickness, coating chemistry, and
overall MR contrast generated; all these need to be carefully
examined for the optimization of USPIONs-based contrast
agents. In vitro and in vivo assay are necessary and unavoidable
that are being undertaken in our laboratories.
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